- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03661905
Enhancing the Acceptability of Psychological Treatments for Obsessive-compulsive Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Obsessive-Compulsive Disorder (OCD) is a serious and often severe mental disorder and one of the leading causes of disability worldwide. Effective psychological interventions for OCD exist, but the prevailing option (Exposure and Response Prevention; ERP) has changed very little since it was established in the 1960's; moreover, it is associated with unacceptably high numbers of individuals who drop out from, or refuse the treatment altogether. This is largely because ERP is a difficult treatment, wherein individuals face their fears with increasing difficulty over time. Just as with the development from early chemotherapy and HIV agents, which were effective, but associated with serious and often severe side effects, it is now time to enhance the acceptability of psychological treatments for OCD.
A novel cognitive therapy (CT) approach is likely to be just as effective as ERP, but markedly more acceptable to those who need it. Although CT for OCD is as effective as ERP, previously tested CTs have failed to incorporate recent experimental research, novel cognitive targets or enhancements to acceptability. Indeed, the investigators recent work on treatment acceptability promises to increase the number of individuals who can fully and successfully engage with the treatment.
The purpose of this research is to enhance the acceptability of cognitive-behavioural treatments for OCD; the investigators aim to accomplish this via a randomized controlled trial comparing traditional ERP against the investigators' novel CT approach. Although the investigators expect both treatments to be effective, the primary hypothesis is that CT will be significantly more acceptable to participants than ERP; this will be assessed by the relative numbers of treatment refusers and dropouts, as well as by participant ratings of treatment acceptability.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stefanie L Lavoie, BA
- Phone Number: 2199 514-848-2424
- Email: stefanie.lavoie@concordia.ca
Study Contact Backup
- Name: Adam S Radomsky, PhD
- Phone Number: 2202 514-848-2424
- Email: adam.radomsky@concordia.ca
Study Locations
-
-
Quebec
-
Montréal, Quebec, Canada, H4B1R6
- Recruiting
- Concordia University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of OCD
- Ability to read, write, and communicate in English
Exclusion Criteria:
- Psychosis
- Diagnosis of bipolar disorder (I or II)
- Current suicidal ideation/intent
- Current substance abuse
- If participants are on medication they must be on a stable dose (i.e. have maintained a consistent dose for at least three months) and agree not to change their medication regimen for the duration of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cognitive Therapy
A modularized, cognitive-behavioural therapy intervention that incorporates evidence gathering and behavioural experiments.
Our CT protocols rely heavily on behavioural experiments which are typically targeted and brief exercises designed to permit clients/patients to gather disconfirmatory evidence about their beliefs.
|
Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD).
Twelve treatment sessions include components to foster cognitive (i.e.
thinking) and behavioural changes.
|
Active Comparator: Behavioural Therapy
Method of behavioral therapy and form of exposure and response prevention therapy in which individuals confront their fears and discontinue their escape response.
Exposures in this protocol are prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
|
Exposure therapy in which individuals confront their fears and discontinue their escape response.
Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidents of participants that drop-out of treatment
Time Frame: Week 2, through treatment completion.
|
The investigators will keep a record of the number of participants that drop-out of treatment.
|
Week 2, through treatment completion.
|
Incidents of participants that refuse treatment
Time Frame: Baseline, up to week two.
|
The investigators will keep a record of the number of participants that refuse the treatment.
|
Baseline, up to week two.
|
Treatment and Acceptability Adherence Scale (TAAS; Milosevic, Levy, Alcolado & Radomsky, 2015)
Time Frame: Through study completion (week 3; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
The TAAS is a validated 10-item self-report questionnaire designed to assess treatment acceptability and anticipated adherence in response to a given treatment for anxiety and related problems.
It is intended to be administered to potential treatment recipients after they have received information about the treatment.
Items are rated on a 7-point Likert-type scale (1 Disagree strongly; 7 Agree strongly) to assess the degree to which participants agree with a variety of statements about a given treatment.
Total scores are obtained by summing across all items after negatively worded items (3, 4, 5, 7, 8 and 10) have been reverse-scored.
Scores may range from 10 to 70, with higher scores indicating greater acceptability of treatment and greater anticipated ability to adhere to it.
|
Through study completion (week 3; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Vancouver Obsessional Compulsive Inventory (VOCI; Thordarson, Radomsky, Rachman, et al., 2004)
Time Frame: Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
The VOCI is a 55-item self-report scale designed to assess obsessive-compulsive symptom severity.
It includes six subscales assessing various symptoms associated with OCD: checking; contamination; obsessions; just right; indecisiveness; and hoarding.
Items are rated on a 5-point Likert-type scale (0 Not at all; 4 Very much), with higher scores indicating higher symptom severity.
|
Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
Anxiety Disorders Interview Schedule for DSM-5 (ADIS-5; Brown & Barlow, 2014)
Time Frame: Through study completion (Baseline; one week post therapy; 6 month follow-up; 12 month follow-up).
|
A semi structured diagnostic interview for anxiety disorders and selected other problems (e.g., depression, substance-related disorders).
It assesses a variety of current and lifetime symptoms associated with anxiety and other (e.g., mood, somatoform, substance abuse, psychotic) disorders, according to DSM-V criteria.
|
Through study completion (Baseline; one week post therapy; 6 month follow-up; 12 month follow-up).
|
The Yale-Brown Obsessive Compulsive Scale (YBOCS; Goodman, Price, Rasmussen, et al., 1989)
Time Frame: Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
This 10-item clinician-administered validated measure consists of two subscales, which assess the severity of participants' obsessions and compulsions and monitors symptom improvement during treatment.
Subscale scores are summed with a range from 0 (no symptoms) to 40 (severe OCD), with a score less than 8 considered as subclinical symptomatology, over 16 as clinically significant symptoms, and over 24 as moderate to severe OCD.
|
Through study completion (Baseline; week 6; one week post therapy; 6 month follow-up; 12 month follow-up).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Adam S Radomsky, PhD, Concordia University, Montreal
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 30006258
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obsessive-Compulsive Disorder
-
Anne Katrine PagsbergCopenhagen Trial Unit, Center for Clinical Intervention Research; Danish Research...Active, not recruitingObsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceDenmark
-
Baylor College of MedicineRecruitingObsessive-Compulsive Disorder | Cognitive Behavioral Therapy | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceUnited States
-
Chaim HuijserLevvelRecruitingObsessive-Compulsive Disorder | Anxiety Disorders and Symptoms | Obsessive-Compulsive Disorder in Children | Obsessive-Compulsive Disorder in AdolescenceNetherlands
-
Stanford UniversityCompletedObsessive Compulsive DisorderUnited States
-
NYU Langone HealthCompletedObsessive Compulsive DisorderUnited States
-
Massachusetts General HospitalActive, not recruitingObsessive Compulsive DisorderUnited States
-
Boston University Charles River CampusCompletedObsessive Compulsive DisorderUnited States
-
Butler HospitalNational Institute of Mental Health (NIMH)CompletedObsessive Compulsive DisorderUnited States
-
Karolinska InstitutetCompletedObsessive Compulsive DisorderSweden
-
Roseli ShavittCompleted
Clinical Trials on Cognitive therapy
-
Henry M. Jackson Foundation for the Advancement...National Alliance for Research on Schizophrenia and DepressionCompletedSuicide, AttemptedUnited States
-
Henry M. Jackson Foundation for the Advancement...Congressionally Directed Medical Research ProgramsCompletedSuicide, AttemptedUnited States
-
Henry M. Jackson Foundation for the Advancement...University of Pennsylvania; University of Michigan; Duke University; US Department... and other collaboratorsUnknownSuicide, Attempted | Suicidal Ideation ActiveUnited States
-
University of BergenCompleted
-
University of MalayaCompletedCognitive Impairment | Mild Traumatic Brain InjuryMalaysia
-
Laval UniversityUniversity of California, BerkeleyCompleted
-
University of RochesterNational Institute of Nursing Research (NINR)CompletedDepression | Sleep | Stress Disorders, Post-TraumaticUnited States
-
University of WashingtonNational Multiple Sclerosis SocietyCompletedMultiple SclerosisUnited States
-
VU University of AmsterdamCompletedMajor Depressive DisorderNetherlands
-
Palo Alto Veterans Institute for ResearchNational Institute of Mental Health (NIMH)Active, not recruitingMobile Application-Based CBT Worksheet Collection | Paper-Based Worksheet CollectionUnited States